Beyond resistance to PARP inhibition: Mechanisms and effective treatment options.

Abstract

Poly-ADP ribosylation polymerase (PARP) inhibition is a promising new strategy that specifically kills malignancies with mutation of BRCA genes. However, as in other agents, it is known that continuous treatment with PARP inhibitors generates acquired resistance in these tumors. In this review, we discuss about the potential mechanisms of acquired resistance to the PARP inhibition that is routed through up-regulation of the NF-κB signaling pathway and furthermore discuss about potential treatment options for malignancies that gain such resistance.